Table 1 Demographics, Model for End-stage Liver Disease (MELD) score, message number, and transplant indication
Characteristic | Controls | Overall | MELD ≥ 30 |
|---|---|---|---|
n = 81 | n = 81 | n = 31 | |
Age (years) | Mean (range) | Mean (range) | Mean (range) |
53.7 (20–70) | 53.8 (19–69) | 52.6 (30–69) | |
Gender | n (%) | n (%) | n (%) |
Female | 32 (40) | 32 (40) | 15 (48.4) |
Race and ethnicity | n (%) | n (%) | n (%) |
Asian | 2 (2.5) | 2 (2.5) | 1 (3.2) |
Black/African American | 14 (17.3) | 14 (17.3) | 8 (25.8) |
Hispanic | 2 (2.4) | 1 (1.2) | 0 (0.0) |
Mixed/Other | 5 (6.2) | 5 (6.2) | 2 (6.5) |
White/Caucasian (non-Hispanic) | 58 (71.6) | 59 (72.8) | 20 (64.5) |
Pre-transplant MELD | – | n (%) | n (%) |
≤9 | – | 5 (6.2) | – |
10–19 | – | 11 (13.6) | – |
20–29 | – | 34 (41.9) | – |
30–39 | – | 23 (28.4) | 23 (74.2) |
≥40 | – | 8 (9.9) | 8 (25.8) |
Message number | Median (IQR) | Median (IQR) | Median (IQR) |
Pre-transplant | 3 (2–5) | 3 (1–10) | 5 (1–18) |
Post-transplant | – | 10 (4–24) | 15 (5–39) |
Transplant indications | n (%) | n (%) | n (%) |
Hepatitis C virus (HCV) cirrhosis | 26 (32.1) | 27 (33.3) | 8 (25.8) |
Nonalcoholic steatohepatitis (NASH) cirrhosis | 14 (17.3) | 14 (17.3) | 4 (12.9) |
Primary sclerosing cholangitis | 9 (11.1) | 12 (14.8) | 10 (32.3) |
Alcoholic cirrhosis | 3 (3.7) | 11 (13.6) | 4 (12.9) |
Abnormal LFTs | 16 (19.8) | – | – |
Other | 13 (16.0) | 17 (21) | 5 (16.1) |
Use of drugs that influence cognition | n (%) | n (%) | |
Narcotics | 23 (28%) | 18 (22%) | |
Antiepileptics | 4 (5%) | 3 (4%) | |
Antipsychotics | 1 (1%) | 3 (4%) | |
Anxieolytics | 17 (21%) | 14 (17%) | |
Other | 2 (2%) | 2 (2%) |
